top of page
Expertise
VIA / cubeRBQM Performance
75%
63%
19%
13%
By Therapeutic Area
KOR
JPN
3%
9%
3%
Phase II
Phase III
Ophthalmology
22%
EU
By Country
9%
6%
Gastroenterology
Phase IV
Endocrinology
OS/PMS
Cardiovascular
Medical Device
ETC.
9%
22%
Hematology
By Phase
Nuerology
3%
3%
22%
9%
9%
Pulmonology
Etc.
eConsent Performance
43%
14%
By Therapeutic Area
KOR
JPN
14%
14%
Phase I
Phase III
14%
43%
Ophthalmology
57%
15%
OS/PMS
14%
Cardiovascular
By Phase
Neurology
Food & supplementary
IIT
Allergology
43%
ETC.
By Country
14%
14%
As of September 2026
Execution Ecosystem
Spero strengthens its integrated execution capabilities across the entire clinical trial lifecycle through strategic collaborations with pharmaceutical and medical device sponsors, fellow CROs, and clinical sites.
Key fields of cooperation
-
Clinical operations (CRO service)
-
Patient recruitment & Engagement
-
Digital-Enabled DCT Operations
Site Management & Monitoring
Dentistry
PMS
3%
Phase IV
3%
46%
Ophthalmology
Gastroenterology
Endocrinology
Cardiovascular
Pulmonology
Hematology
10%
6%
8%
10%
23%
By Phase
Others
Medical Device (incl. DTx)
IIT
OS
Phase I
Phase III
Phase II
4%
4%
12%
4%
15%
Neurology
2%
4%
10%
13%
13%
28%
28%
Statistics
Data Management
Medical Writing
Project Management
Site Startup
*Site Management : VIA/cubeRBQM service included.
2%
4%
PMS
Phase IV
Others
QA/QC
Dermatology
5%
10%
10%
8%
10%
2%
Vaccines
Oncology
Achievement
Spero started patient recruitment service in 2021 and has been accumulating achievements in various CRO service areas since it expanded its business to DCT in 2022.
Therapeutic Area & Phase
Experienced Staffs and Potential expertise
Spero is enhancing its expertise and operational efficiency for the successful execution of clinical trials
By Therapeutic Area
Clinical Operation
Full Support Service
Spero supports all phases of clinical trials, and prioritizes customer requirements, and the safety of clinical trials
By Operation service
6%
6%
bottom of page